Development of a Cloud Platform for Advanced Diagnostics Based on Clinical and Omics Data.
A legfontosabb adatok
- Ki végzi
- Istituto Giannina Gaslini
- Hol
- Olaszország3 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Befejeződött
- Résztvevők
- 73 fő vett részt
- Kezdés
- 2025. márc. 12.
- Befejezés
- 2025. okt. 31.
- A vizsgálat típusa
- Megfigyeléses, 4 csoport
- A regiszteradat frissítve
- 2026. október 22.
Ki vehet részt
- Életkor
- Legfeljebb 25 év
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 8 feltétel megnézéseKevesebb
Ki vehet részt
- Age 0-25 years
- Newly diagnosed active disease or unstable disease (ongoing attacks despite treatment), whether genetically confirmed or still undiagnosed
- The patient or their legal representative provides informed consent to participate in the study, including undergoing omics analyses and agreeing to the sharing and use of their clinical and omics data for subsequent analyses
- Monogenic SAID: Patients with clinical and genetic findings consistent with a monogenic SAID belonging to one of the following categories: inflammasomopathies, unfolded protein response (UPR) and cellular stress disorders, type I interferonopathies, actinopathies, NF-κB hyperactivation disorders, or DADA2. Physician Global Assessment (PGA) > 2 on a 0-10 visual analogue scale (VAS) and elevated C-reactive protein (CRP) levels
- Multifactorial/complex SAID: Patients with clinical manifestations consistent with PFAPA, SURF (as defined in Papa R et al., 2020), chronic recurrent multifocal osteomyelitis (CRMO)/SAPHO syndrome, or systemic juvenile idiopathic arthritis (sJIA). PGA > 2 on a 0-10 VAS and elevated CRP levels
- Undifferentiated SAID (uSAID): Patients with clinical manifestations consistent with a SAID, after exclusion of defined monogenic or multifactorial/complex autoinflammatory diseases based on clinical and/or genetic findings. PGA > 2 on a 0-10 VAS and elevated CRP levels
- Fibromyalgia (FM): Widespread pain with symptoms present for at least 3 months. Patients meeting the clinical criteria defined in Wolfe et al. (2016)
Ki nem vehet részt
- Inflammatory bowel diseases or other inflammatory conditions that may mimic SAIDs (e.g., haematological disorders, malignancies, and immunodeficiencies)
Hol van ez a vizsgálat?
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
This study aims to explore how information from different types of biological tests, such as genetic, protein, and fat-related analyses, can help doctors better identify and distinguish patients with systemic autoinflammatory diseases (SAIDs), including undifferentiated or complex forms of these conditions (uSAIDs and SAIDs), as well as fibromyalgia. The goal is to improve diagnosis and help identify the most appropriate treatments and care options for each patient.
A teljes eredeti leírásKevesebb
The study will also develop computer-based tools to identify important biological patterns in patients' medical records and laboratory results. These tools will help doctors interpret each patient's individual case and better understand their condition.
Finally, the study will bring together biological test results, clinical information, and the findings from these analyses in a single, comprehensive health record. This record will have an easy-to-use interface designed to support patients' care teams. Its usefulness in everyday clinical practice will then be evaluated.
A vizsgálat 4 csoportja
- monogenic SAID
Patients with clinical and genetic findings consistent with a monogenic SAID belonging to one of the following categories: inflammasomopathies, unfolded protein response (UPR) and cellular stress disorders, type I interferonopathies, actinopathies, NF-κB hyperactivation disorders, or DADA2. Physician Global Assessment (PGA) \> 2 on a 0-10 visual analogue scale (VAS) and elevated C-reactive protein (CRP) levels.
- Multifactorial/complex SAID
Patients with clinical manifestations consistent with PFAPA, SURF (as defined in Papa R et al., 2020), chronic recurrent multifocal osteomyelitis (CRMO)/SAPHO syndrome, or systemic juvenile idiopathic arthritis (sJIA). Physician Global Assessment (PGA) \> 2 on a 0-10 visual analogue scale (VAS) and elevated C-reactive protein (CRP) levels.
- undifferentiated SAID
Patients with clinical manifestations consistent with a SAID, after excluding defined monogenic or multifactorial/complex autoinflammatory diseases based on clinical and/or genetic findings. Physician Global Assessment (PGA) \> 2 on a 0-10 visual analogue scale (VAS) and elevated C-reactive protein (CRP) levels.
- Fibromyalgia
Widespread pain with symptoms persisting for at least 3 months. Patients meeting the clinical criteria defined in Wolfe et al. (2016).
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Development of a Cloud Platform for Advanced Diagnostics Based on Clinical and Omics Data - Sviluppo di Una Piattaforma Cloud Per la Diagnostica Avanzata Basata su Dati Clinico-omici
- A regiszteradat frissítve
- 2026. október 22.